1. Home
  2. CMU vs IMUX Comparison

CMU vs IMUX Comparison

Compare CMU & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Municipal Income Trust

CMU

MFS Municipal Income Trust

HOLD

Current Price

$3.62

Market Cap

92.2M

Sector

Finance

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$1.17

Market Cap

75.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMU
IMUX
Founded
1987
2016
Country
United States
United States
Employees
N/A
66
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.2M
75.2M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
CMU
IMUX
Price
$3.62
$1.17
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$4.25
AVG Volume (30 Days)
106.3K
4.7M
Earning Date
01-01-0001
05-29-2026
Dividend Yield
4.08%
N/A
EPS Growth
N/A
38.00
EPS
0.07
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$51.64
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.18
$0.51
52 Week High
$3.69
$1.51

Technical Indicators

Market Signals
Indicator
CMU
IMUX
Relative Strength Index (RSI) 53.97 58.29
Support Level $3.48 $0.64
Resistance Level $3.69 N/A
Average True Range (ATR) 0.04 0.12
MACD -0.00 0.02
Stochastic Oscillator 46.46 51.49

Price Performance

Historical Comparison
CMU
IMUX

About CMU MFS Municipal Income Trust

Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company invest various top Healthcare companies, Airport, Universities (Secondary Schools), Universities (Dormitories), and many more, out of maximum revenue is gained from Healthcare Hospitals and Long Term Care.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: